Brief: Adicet Bio Says Public Offering Price Of $2.40 Per Share
U.S. STOCKS ON THE MOVE-Crypto stocks, US insurers, EPAM Systems
U.S. STOCKS ON THE MOVE-Apple, Lamb Weston, Dyne Therapeutics
Adicet jumps on plan to test cell therapy for autoimmune diseases
Brief: Adicet Says Co Expanding Clinical Development Of ADI-001 Into Autoimmune Diseases
U.S. RESEARCH ROUNDUP-Aclaris Therapeutics, Beauty Health Co, Vicarious Surgical
Brief: Adicet Bio Q3 Basic EPS USD -1.16
Adicet Bio Inc expected to post a loss of 74 cents a share - Earnings Preview
Adicet Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Adicet Bio Q2 Basic EPS USD -0.75
Adicet Bio Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Adicet Announces Appointment Of Katie Peng To Board Of Directors
Brief: Adicet Bio Appoints Katie Peng To Board
U.S. RESEARCH ROUNDUP- Constellation Brands, Northern Trust, Roper Technologies
Brief: Adicet Bio Reports Positive Data From AdI-001 Phase 1 Trial In Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
U.S. STOCKS ON THE MOVE-Brady, Madison Square Garden Entertainment, Bowlero
U.S. STOCKS ON THE MOVE-Hawkins, Netflix, Alibaba Group
U.S. STOCKS ON THE MOVE-Dole, Canada Goose, Regency Centers
Adicet Bio rises as cancer therapy shows promise in pre-clinical study